<?xml version='1.0' encoding='utf-8'?>
<document id="15496222"><sentence text="Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses."><entity charOffset="29-42" id="DDI-PubMed.15496222.s1.e0" text="donepezil HCl" /><entity charOffset="47-55" id="DDI-PubMed.15496222.s1.e1" text="levodopa" /><entity charOffset="56-65" id="DDI-PubMed.15496222.s1.e2" text="carbidopa" /><pair ddi="false" e1="DDI-PubMed.15496222.s1.e0" e2="DDI-PubMed.15496222.s1.e0" /><pair ddi="false" e1="DDI-PubMed.15496222.s1.e0" e2="DDI-PubMed.15496222.s1.e1" /><pair ddi="false" e1="DDI-PubMed.15496222.s1.e0" e2="DDI-PubMed.15496222.s1.e2" /><pair ddi="false" e1="DDI-PubMed.15496222.s1.e1" e2="DDI-PubMed.15496222.s1.e1" /><pair ddi="false" e1="DDI-PubMed.15496222.s1.e1" e2="DDI-PubMed.15496222.s1.e2" /></sentence><sentence text="The use of acetylcholinesterase inhibitors for the treatment of comorbid Alzheimer's disease in Parkinson's disease (PD) patients stabilized on a levodopa regimen may potentially disrupt cholinergic balance"><entity charOffset="146-154" id="DDI-PubMed.15496222.s2.e0" text="levodopa" /></sentence><sentence text=" This randomized, double-blind, crossover study investigated the safety of, and possible drug-drug interaction between, donepezil HCl and levodopa/carbidopa"><entity charOffset="120-133" id="DDI-PubMed.15496222.s3.e0" text="donepezil HCl" /><entity charOffset="138-146" id="DDI-PubMed.15496222.s3.e1" text="levodopa" /><entity charOffset="147-156" id="DDI-PubMed.15496222.s3.e2" text="carbidopa" /><pair ddi="false" e1="DDI-PubMed.15496222.s3.e0" e2="DDI-PubMed.15496222.s3.e0" /><pair ddi="false" e1="DDI-PubMed.15496222.s3.e0" e2="DDI-PubMed.15496222.s3.e1" /><pair ddi="false" e1="DDI-PubMed.15496222.s3.e0" e2="DDI-PubMed.15496222.s3.e2" /><pair ddi="false" e1="DDI-PubMed.15496222.s3.e1" e2="DDI-PubMed.15496222.s3.e1" /><pair ddi="false" e1="DDI-PubMed.15496222.s3.e1" e2="DDI-PubMed.15496222.s3.e2" /></sentence><sentence text="" /><sentence text="Twenty-five patients with PD who were taking physician-optimized doses of levodopa/carbidopa (with daytime dosing intervals of 4-8 h) were administered once-daily doses of either donepezil HCl (5 mg) or placebo for 15 days, in two treatment periods, separated by a washout of at least 2 weeks"><entity charOffset="74-82" id="DDI-PubMed.15496222.s5.e0" text="levodopa" /><entity charOffset="83-92" id="DDI-PubMed.15496222.s5.e1" text="carbidopa" /><entity charOffset="179-192" id="DDI-PubMed.15496222.s5.e2" text="donepezil HCl" /><pair ddi="false" e1="DDI-PubMed.15496222.s5.e0" e2="DDI-PubMed.15496222.s5.e0" /><pair ddi="false" e1="DDI-PubMed.15496222.s5.e0" e2="DDI-PubMed.15496222.s5.e1" /><pair ddi="false" e1="DDI-PubMed.15496222.s5.e0" e2="DDI-PubMed.15496222.s5.e2" /><pair ddi="false" e1="DDI-PubMed.15496222.s5.e1" e2="DDI-PubMed.15496222.s5.e1" /><pair ddi="false" e1="DDI-PubMed.15496222.s5.e1" e2="DDI-PubMed.15496222.s5.e2" /></sentence><sentence text=" Some patients took a second dose of levodopa/carbidopa after 4 h, therefore subanalysis of the levodopa/carbidopa data was conducted up to 4 h and 8 h after dosing"><entity charOffset="37-45" id="DDI-PubMed.15496222.s6.e0" text="levodopa" /><entity charOffset="46-55" id="DDI-PubMed.15496222.s6.e1" text="carbidopa" /><entity charOffset="96-104" id="DDI-PubMed.15496222.s6.e2" text="levodopa" /><entity charOffset="105-114" id="DDI-PubMed.15496222.s6.e3" text="carbidopa" /><pair ddi="false" e1="DDI-PubMed.15496222.s6.e0" e2="DDI-PubMed.15496222.s6.e0" /><pair ddi="false" e1="DDI-PubMed.15496222.s6.e0" e2="DDI-PubMed.15496222.s6.e1" /><pair ddi="false" e1="DDI-PubMed.15496222.s6.e0" e2="DDI-PubMed.15496222.s6.e2" /><pair ddi="false" e1="DDI-PubMed.15496222.s6.e0" e2="DDI-PubMed.15496222.s6.e3" /><pair ddi="false" e1="DDI-PubMed.15496222.s6.e1" e2="DDI-PubMed.15496222.s6.e1" /><pair ddi="false" e1="DDI-PubMed.15496222.s6.e1" e2="DDI-PubMed.15496222.s6.e2" /><pair ddi="false" e1="DDI-PubMed.15496222.s6.e1" e2="DDI-PubMed.15496222.s6.e3" /><pair ddi="false" e1="DDI-PubMed.15496222.s6.e2" e2="DDI-PubMed.15496222.s6.e2" /><pair ddi="false" e1="DDI-PubMed.15496222.s6.e2" e2="DDI-PubMed.15496222.s6.e3" /></sentence><sentence text=" Twenty-six healthy matched controls received open-label donepezil HCl only, for a single 15-day period"><entity charOffset="57-70" id="DDI-PubMed.15496222.s7.e0" text="donepezil HCl" /></sentence><sentence text=" Blood samples were collected before, during and after the 15 doses of donepezil HCl for pharmacokinetic (PK) assessments"><entity charOffset="71-84" id="DDI-PubMed.15496222.s8.e0" text="donepezil HCl" /></sentence><sentence text=" Pharmacokinetic parameters included maximum attained plasma drug concentration (C(max)), time at which C(max) is attained (t(max)), plasma drug concentration at steady state (C(ss)), and area under the drug concentration-time curve over the dosing interval" /><sentence text=" Safety assessments included monitoring adverse events, and the Unified Parkinson's Disease Rating Scale (UPDRS) motor examination" /><sentence text="" /><sentence text="The mean age of all subjects was 72" /><sentence text="6 +/- 1" /><sentence text="3 years" /><sentence text=" Donepezil PK assessments of PD patients receiving levodopa/carbidopa were similar to the PK results from healthy controls who received donepezil HCl only (mean AUC(0-12 h)= 281"><entity charOffset="1-10" id="DDI-PubMed.15496222.s15.e0" text="Donepezil" /><entity charOffset="51-59" id="DDI-PubMed.15496222.s15.e1" text="levodopa" /><entity charOffset="60-69" id="DDI-PubMed.15496222.s15.e2" text="carbidopa" /><entity charOffset="136-149" id="DDI-PubMed.15496222.s15.e3" text="donepezil HCl" /><pair ddi="false" e1="DDI-PubMed.15496222.s15.e0" e2="DDI-PubMed.15496222.s15.e0" /><pair ddi="false" e1="DDI-PubMed.15496222.s15.e0" e2="DDI-PubMed.15496222.s15.e1" /><pair ddi="false" e1="DDI-PubMed.15496222.s15.e0" e2="DDI-PubMed.15496222.s15.e2" /><pair ddi="false" e1="DDI-PubMed.15496222.s15.e0" e2="DDI-PubMed.15496222.s15.e3" /><pair ddi="false" e1="DDI-PubMed.15496222.s15.e1" e2="DDI-PubMed.15496222.s15.e1" /><pair ddi="false" e1="DDI-PubMed.15496222.s15.e1" e2="DDI-PubMed.15496222.s15.e2" /><pair ddi="false" e1="DDI-PubMed.15496222.s15.e1" e2="DDI-PubMed.15496222.s15.e3" /><pair ddi="false" e1="DDI-PubMed.15496222.s15.e2" e2="DDI-PubMed.15496222.s15.e2" /><pair ddi="false" e1="DDI-PubMed.15496222.s15.e2" e2="DDI-PubMed.15496222.s15.e3" /></sentence><sentence text="6 +/- 17" /><sentence text="6 and 268" /><sentence text="6 +/- 19" /><sentence text="9 ng" /><sentence text="h ml(-1), respectively)" /><sentence text=" Carbidopa PK were not significantly altered by the concomitant administration of multiple doses of donepezil HCl, compared with when PD patients received placebo (mean AUC(0-8 h)= 921"><entity charOffset="100-113" id="DDI-PubMed.15496222.s21.e0" text="donepezil HCl" /></sentence><sentence text="8 +/- 160 and 821" /><sentence text="8 +/- 113 ng" /><sentence text="h ml(-1), respectively)" /><sentence text=" Four hours after administration of donepezil HCl in PD patients, AUC(0-4 h), C(max) and C(ss) of levodopa were higher than when PD patients received placebo (P &lt; 0"><entity charOffset="36-49" id="DDI-PubMed.15496222.s25.e0" text="donepezil HCl" /><entity charOffset="98-106" id="DDI-PubMed.15496222.s25.e1" text="levodopa" /><pair ddi="false" e1="DDI-PubMed.15496222.s25.e0" e2="DDI-PubMed.15496222.s25.e0" /><pair ddi="false" e1="DDI-PubMed.15496222.s25.e0" e2="DDI-PubMed.15496222.s25.e1" /></sentence><sentence text="05)" /><sentence text=" Eight hours after donepezil HCl, however, only C(max) and t(max) were observed to change compared with when PD patients received placebo (mean C(max) = 2652 +/- 429 and 2077 +/- 276 ng ml(-1), respectively; mean t(max) = 1"><entity charOffset="19-32" id="DDI-PubMed.15496222.s27.e0" text="donepezil HCl" /></sentence><sentence text="7 +/- 0" /><sentence text="4 and 2" /><sentence text="9 +/- 0" /><sentence text="5 h, respectively; P&lt; or = 0" /><sentence text="05)" /><sentence text=" The number of PD patients who experienced at least one adverse event during the study (13/25) was higher when they received donepezil HCl than when they received placebo (5/25), but was the same as healthy subjects who received donepezil HCl only (13/26)"><entity charOffset="125-138" id="DDI-PubMed.15496222.s33.e0" text="donepezil HCl" /><entity charOffset="229-242" id="DDI-PubMed.15496222.s33.e1" text="donepezil HCl" /><pair ddi="false" e1="DDI-PubMed.15496222.s33.e0" e2="DDI-PubMed.15496222.s33.e0" /><pair ddi="false" e1="DDI-PubMed.15496222.s33.e0" e2="DDI-PubMed.15496222.s33.e1" /></sentence><sentence text=" There were no significant differences in change from baseline on the UPDRS motor examination parameters in PD patients when they took donepezil HCl and when they took placebo"><entity charOffset="135-148" id="DDI-PubMed.15496222.s34.e0" text="donepezil HCl" /></sentence><sentence text="" /><sentence text="No clinically significant drug-drug interactions between donepezil HCl and levodopa/carbidopa were observed at steady state"><entity charOffset="57-70" id="DDI-PubMed.15496222.s36.e0" text="donepezil HCl" /><entity charOffset="75-83" id="DDI-PubMed.15496222.s36.e1" text="levodopa" /><entity charOffset="84-93" id="DDI-PubMed.15496222.s36.e2" text="carbidopa" /><pair ddi="false" e1="DDI-PubMed.15496222.s36.e0" e2="DDI-PubMed.15496222.s36.e0" /><pair ddi="false" e1="DDI-PubMed.15496222.s36.e0" e2="DDI-PubMed.15496222.s36.e1" /><pair ddi="false" e1="DDI-PubMed.15496222.s36.e0" e2="DDI-PubMed.15496222.s36.e2" /><pair ddi="false" e1="DDI-PubMed.15496222.s36.e1" e2="DDI-PubMed.15496222.s36.e1" /><pair ddi="false" e1="DDI-PubMed.15496222.s36.e1" e2="DDI-PubMed.15496222.s36.e2" /></sentence><sentence text=" The small changes in the pharmacokinetics of levodopa did not result in any change in motor symptoms"><entity charOffset="46-54" id="DDI-PubMed.15496222.s37.e0" text="levodopa" /></sentence><sentence text=" Co-administration of the two drugs led to a small increase in adverse events compared with administration of levodopa/carbidopa alone in PD patients"><entity charOffset="110-118" id="DDI-PubMed.15496222.s38.e0" text="levodopa" /><entity charOffset="119-128" id="DDI-PubMed.15496222.s38.e1" text="carbidopa" /><pair ddi="false" e1="DDI-PubMed.15496222.s38.e0" e2="DDI-PubMed.15496222.s38.e0" /><pair ddi="false" e1="DDI-PubMed.15496222.s38.e0" e2="DDI-PubMed.15496222.s38.e1" /></sentence><sentence text=" These adverse events, however, were consistent with donepezil's cholinomimetic effect, and their incidence was comparable to that observed following the administration of donepezil HCl alone"><entity charOffset="172-185" id="DDI-PubMed.15496222.s39.e0" text="donepezil HCl" /></sentence><sentence text="" /></document>